Daniel Lebovic

3.5k citations
42 papers · 1.0k · h-index 14

Impact in

  • Hematology top 2%
    • Multiple Myeloma Research and Treatments
  • Oncology top 10%
    • Peptidase Inhibition and Analysis
    • CAR-T cell therapy research

Papers in

Co-authors
Andrzej Jakubowiak (11 shared papers)Mark Kaminski (11 shared papers)Kent A. Griffith (12 shared papers)Ravi Vij (7 shared papers)Sundar Jagannath (7 shared papers)Keith Stockerl‐Goldstein (6 shared papers)Tara Anderson (6 shared papers)Dominik Dytfeld (7 shared papers)
Journals
Blood (23 papers)Journal of Clinical Oncology (3 papers)Clinical Cancer Research (2 papers)British Journal of Haematology (2 papers)JAMA Network Open (1 paper)
Partner nations
United StatesPolandGermany

In The Last Decade

Daniel Lebovic

39 papers receiving 1.0k citations

Peers

Daniel Lebovic
Comparison fields: 5 of 61
  • Hematology 547
  • Oncology 379
  • Genetics 124
  • Pathology and Forensic Medicine 182
  • Molecular Biology 644
Replace Caitlin Costello with:
Caitlin Costello United States
Katarina Luptakova United States
P. Leif Bergsagel United States
Sarah Brennan United States
Simon He Australia
Sophie Derenne France
Tiffany Khong Australia
C. Vasselon France
Georgios Z. Rassidakis United States
Daniel Lebovic relative to Caitlin Costello United States Caitlin Costello's profile →
Citations per field
00.5×2×4×6×8.5×
Caitlin Costello · 1×
Citations per year

Countries citing papers authored by Daniel Lebovic

Since Specialization
Citations

This map shows the geographic impact of Daniel Lebovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lebovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lebovic more than expected).

Fields of papers citing papers by Daniel Lebovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Lebovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lebovic. The network helps show where Daniel Lebovic may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Lebovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Lebovic Line = papers co-authored together Daniel Lebovic links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Blood ·Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian K. Nordgren, Kristen Detweiler‐Short, Keith Stockerl‐Goldstein, Asra Ahmed, Terri L. Jobkar, Diane E. Durecki, Kathryn McDonnell, M. Mietzel, Daniel R. Couriel, Mark Kaminski, Ravi Vij
2012322
2
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Clinical Cancer Research ·Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial
2015166
3
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma
Blood ·Hongxiu Li, Mark Kaminski, Yifeng Li, Mehmet Ali Yıldız, Peter Ouillette, Siân Jones, Heather Fox, Kathryn Jacobi, Kamlai Saiya-Cork, Dale L. Bixby, Daniel Lebovic, Diane Roulston, Kerby Shedden, Michael Sabel, Lawrence J. Marentette, Vincent M. Cimmino, Alfred E. Chang, Sami N. Malek
2014135
4
Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Clinical Cancer Research ·Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark W. Brunvand, André Goy, (unknown), Ephraim P. Hochberg, Sreeni Yalamanchili, Robert S. Kahn, Dan Lü, Priya Agarwal, Randall Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Waye Chu, Bruce D. Cheson
201674
5
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
British Journal of Haematology ·Paul G. Richardson, William Bensinger, Carol Ann Huff, Caitlin Costello, Nikoletta Lendvai, Jesús G. Berdeja, Larry D. Anderson, David S. Siegel, Daniel Lebovic, Sundar Jagannath, Jacob P. Laubach, Keith Stockerl‐Goldstein, Long Kwei, Fong Clow, Laurence Elias, Zeena Salman, Thorsten Graef, Elizabeth Bilotti, Ravi Vij
201832
6
Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
British Journal of Haematology ·Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum, Myo Htut, David H. Vesole, Jesús G. Berdeja, Michaela Liedtke, Ajai Chari, Stephen D. Smith, Daniel Lebovic, Noopur Raje, Catriona Byrne, Eileen Liao, Neeraj Gupta, Alessandra Di Bacco, Jose Estevam, Deborah Berg, Rachid Baz
201828
7
Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
Blood ·Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum, Myo Htut, David H. Vesole, Jesús G. Berdeja, Michaela Liedtke, Ajai Chari, Stephen D. Smith, Daniel Lebovic, Deborah Berg, Eileen Liao, Neeraj Gupta, Alessandra Di Bacco, Jose Estevam, Ai‐Min Hui, Rachid Baz
201328
8
Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma
Blood ·Marc S. Raab, Enrique M. Ocio, Sheeba K. Thomas, Andreas Guenther, Daniel Lebovic, Shaji Kumar, Andrzej Jakubowiak, Dongweon Song, (unknown), David Hynds, K. Gary J. Vanasse, Yeow Tee Goh
201327
9
Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma
Blood ·Marc S. Raab, Enrique M. Ocio, Sheeba K. Thomas, Andreas Günther, Yeow-Tee Goh, Daniel Lebovic, Andrzej Jakubowiak, Dongweon Song, F Xiang, Apurva Patel, K. Gary J. Vanasse, Shaji Kumar
201427
10
Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience
Clinical Lymphoma Myeloma & Leukemia ·Daniel Lebovic, Ling Zhang, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Daniel M. Sullivan, José L. Ochoa-Bayona, Mohamed A. Kharfan‐Dabaja, Rachid Baz
201126
11
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
Blood ·Andrzej Jakubowiak, Dominik Dytfeld, Sundar Jagannath, David H. Vesole, Tara Anderson, Brian K. Nordgren, Kristen Detweiler‐Short, Daniel Lebovic, Keith Stockerl‐Goldstein, Kent A. Griffith, Terri L. Jobkar, Diane E. Durecki, Sandra Wear, Robert F Ott, Ammar Al-Zoubi, M. Mietzel, Mohamed Hussein, Daniel R. Couriel, Joseph A. Leveque, Ravi Vij
201120
12
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
Blood ·Suzanne Trudel, P. Leif Bergsagel, Seema Singhal, Rubén Niesvizky, Raymond L. Comenzo, William Bensinger, Daniel Lebovic, YounJeong Choi, Dan Lü, Dorothy French, Elicia Penuel, William Ho, Keith Stewart
201214
13
Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
Journal of Clinical Oncology ·Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Jagoda Jasielec, Kathryn McDonnell, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Elaine G. Chottiner, Tara Anderson, Kristen Detweiler‐Short, Keith Stockerl‐Goldstein, Asra Ahmed, Terri L. Jobkar, Diane E. Durecki, M. Mietzel, Daniel R. Couriel, Ravi Vij, Mark Kaminski
201313
14
Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)
Blood ·Ranjana H. Advani, Andy I. Chen, Daniel Lebovic, Mark W. Brunvand, André Goy, Julie Chang, Ephraim P. Hochberg, Sreeni Yalamanchili, Robert S. Kahn, Dan Lu, Akiko Chai, Yu‐Waye Chu, Bruce D. Cheson
201313
15
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis
Leukemia & lymphoma ·Rachid Baz, Mehul Patel, Elizabeth Finley-Oliver, Daniel Lebovic, Mohamad A. Hussein, Kena C. Miller, Margaret Wood, Taimur Sher, Kelvin Lee, Asher Chanan‐Khan
201013
16
Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
Blood ·Andrzej Jakubowiak, Dominik Dytfeld, Sundar Jagannath, David H. Vesole, Tara Anderson, Brian K. Nordgren, Daniel Lebovic, Keith Stockerl‐Goldstein, Kent A. Griffith, Melissa A. Hill, Colleen K Harvey, Akari M. Dollard, Robert F Ott, Susan L. Kelley, Jennifer Barrickman, Michael Kauffman, Ravi Vij
201012
17
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results
Blood ·Ravi Vij, Carol Ann Huff, William Bensinger, David S. Siegel, Sundar Jagannath, Jesús G. Berdeja, Nikoletta Lendvai, Daniel Lebovic, Larry D. Anderson, Caitlin Costello, Keith Stockerl‐Goldstein, Jacob P. Laubach, Laurence Elias, Fong Clow, Maria Fardis, Thorsten Graef, Elizabeth Bilotti, Paul G. Richardson
201411
18
A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Blood ·Ranjana H. Advani, Daniel Lebovic, Mark W. Brunvand, Andy I. Chen, André Goy, Julie Chang, Lauren S. Maeda, William Ho, Robert S. Kahn, Dan Lu, Zheng Su, Yu‐Waye Chu, Bruce D. Cheson
201211
19
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial
Leukemia & lymphoma ·Dominik Dytfeld, Kent A. Griffith, Judah Friedman, Daniel Lebovic, Colleen K Harvey, Mark Kaminski, Andrzej Jakubowiak
201111
20
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab
Leukemia & lymphoma ·Rebecca Elstrom, Jia Ruan, Paul J. Christos, Peter Martin, Daniel Lebovic, Joseph R. Osborne, Stanley J. Goldsmith, June Greenberg, Richard R. Furman, Anca M. Avram, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, John P. Leonard, Mark Kaminski
201411

About Daniel Lebovic

Daniel Lebovic is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Oncology and Genetics, having authored 42 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (12 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Peptidase Inhibition and Analysis (5 papers), Cancer Treatment and Pharmacology (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Hematology (547 citations), Oncology (379 citations), Genetics (124 citations), Pathology and Forensic Medicine (182 citations) and Molecular Biology (644 citations). Daniel Lebovic has collaborated with scholars based in United States, Poland and Germany. Frequent co-authors include Andrzej Jakubowiak, Mark Kaminski, Kent A. Griffith, Ravi Vij, Sundar Jagannath, Keith Stockerl‐Goldstein, Tara Anderson, Dominik Dytfeld, Kristen Detweiler‐Short and Kathryn McDonnell. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Haematology and JAMA Network Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caitlin CostelloBreakdown of academic impact, for papers by Katarina LuptakovaBreakdown of academic impact, for papers by P. Leif BergsagelBreakdown of academic impact, for papers by Sarah BrennanBreakdown of academic impact, for papers by Simon HeBreakdown of academic impact, for papers by Sophie DerenneBreakdown of academic impact, for papers by Tiffany KhongBreakdown of academic impact, for papers by C. VasselonBreakdown of academic impact, for papers by Georgios Z. Rassidakis